TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of changes in equity
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number of shares (in millions) | Stated value | Additional paid-in capital | Retained earnings (accumulated deficit) | Accumulated other comprehensive income (loss) | Treasury shares | Total Teva share- holders’ equity | Non-controlling interests | Total equity | |
| (U.S. dollars in millions) | |||||||||
| Balance at January 1, 2021 | 1,202 | 57 | 27,443 | (10,946) | (2,399) | (4,128) | 10,026 | 1,035 | 11,061 |
| Changes during 2021: | |||||||||
| Net income (loss) | 417 | 417 | 39 | 456 | |||||
| Other comprehensive income (loss) | (283) | (283) | (107) | (391) | |||||
| Issuance of shares | 7 | * | * | * | * | ||||
| Stock-based compensation expense | 119 | 119 | 119 | ||||||
| Transactions with non-controlling interests | (2) | (2) | |||||||
| Balance at December 31, 2021 | 1,209 | 57 | 27,561 | (10,529) | (2,683) | (4,128) | 10,278 | 966 | 11,244 |
| Changes during 2022: | |||||||||
| Net income (loss) | (2,446) | (2,446) | (53) | (2,499) | |||||
| Other comprehensive income (loss) | (154) | (154) | (116) | (270) | |||||
| Issuance of Shares | 8 | * | 1 | 1 | 1 | ||||
| Stock-based compensation expense | 124 | 124 | 124 | ||||||
| Transactions with non-controlling interests | (2) | (2) | |||||||
| Balance at December 31, 2022 | 1,217 | 57 | 27,688 | (12,975) | (2,838) | (4,128) | 7,804 | 794 | 8,598 |
| Changes during 2023: | |||||||||
| Net income (loss) | (559) | (559) | (56) | (615) | |||||
| Other comprehensive income (loss) | 141 | 141 | (50) | 91 | |||||
| Issuance of Shares | 10 | * | * | * | * | ||||
| Stock-based compensation expense | 121 | 121 | 121 | ||||||
| Dividend to non-controlling interests ** | (68) | (68) | |||||||
| Balance at December 31, 2023 | 1,227 | $57 | $27,807 | $(13,534) | $(2,697) | $(4,128) | $7,506 | $620 | $8,126 |
| * | Represents an amount less than $0.5 million. |
|---|
| ** | Mainly in connection with a declaration of dividends to non-controlling interests in Teva’s joint venture in Japan. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.